New injection shows promise for heart failure patients

NCT ID NCT06264310

Completed Disease control Sponsor: River 2 Renal Corp. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called R2R01 in 33 people with worsening heart failure. Participants received either R2R01 or a placebo alongside their usual treatments. The goal was to see if the drug is safe and helps reduce fluid buildup in the heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: R2R01 (a relaxin agonist given as an injection)
What this could lead to: If successful, this could lead to a new add-on treatment to help manage worsening heart failure and reduce hospitalizations.
What could go wrong: This is an early Phase 2 trial with only 33 participants, so results may not apply widely. The drug may not show clear benefit or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WORSENING HEART FAILURE (WHF)

Contacts and locations

Locations

Amavita Clinical Research

Miami, Florida, 33137, United States
C&R Research

Fort Meyers, Florida, 33919, United States
C&R Research

Hialeah, Florida, 33013, United States
Encore Clinical Research

Inverness, Florida, 34452, United States
Encore Clinical Research

Jacksonville, Florida, 32216, United States
J&S Studies

College Station, Texas, 77845, United States
Lake Country

Eatonton, Georgia, 31024, United States
Thomas Hospital

Fairhope, Alabama, 36532, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.